Influenza A - A Drug Pipeline Analysis Report by Technavio

LONDON--(BUSINESS WIRE)-- Technavio has announced their latest drug pipeline analysis report on influenza A. The report includes a comprehensive research on the pipeline molecules under investigation by the pharmaceutical companies within the defined data collection period for the treatment of influenza A. The report also includes a study of the pipeline molecules in various stages including, on-going clinical trials, discovery, and pre-clinical.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180913005416/en/

Technavio has published a new report on the drug development pipeline for the treatment of influenza A, including a detailed study of the pipeline molecules. (Photo: Business Wire)

Influenza A: An overview

Influenza A is a contagious disease, which is caused by the influenza virus. It spreads rapidly from one person to another. Influenza, also known as flu, is of three types, namely influenza A, influenza B, influenza C. Influenza A is a type of virus that infects animals, especially wild aquatic birds. It is continuously changing and is responsible for the large flu epidemics. It is transmitted to other species and can cause outbreaks in humans. It can cause moderate to severe illness and can affect all age groups. People with a weakened immune system are likely to get infected more frequently. Influenza A is of high risk in young children, the elderly, and pregnant women.

In January 2011, according to the estimation of Centers for Disease Control and Prevention, the pandemic H1N1 influenza virus infected more than 60 million Americans and led to more than 270,000 hospitalized and 12,500 deaths.

This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing

Influenza A: Segmentation of pipeline molecules

Technavio’s research segments the pipeline molecules based on different phases of drug development including, therapies employed, route of administration (RoA), mechanism of action (MoA), therapeutic modality, and the targets for the drugs under development. In the current drug pipeline, the most preferred therapeutic modality is vaccine, with more than 52% of the pipeline molecules administered through this mode.

Between companies and institutions, institutions led the drug development space for the treatment of influenza A. Various institutes, universities, and hospitals, such as Innovate UK, the University of Massachusetts, University of Georgia, and the National Institutes of Health are conducting studies on influenza A. Some of the key players include Visterra, Seqirus, Kineta, iQur, and GREEN CROSS .

Looking for more information? Request your free sample today

Some of the key topics covered in the report include:

1. Scope of the Report

2. Regulatory Framework

3. Drug Development Landscape

• Drugs under development

4. Drug Development Strategies

• Therapies employed
• Route of administration
• Therapeutic modality
• Mechanism of action

5. Recruitment Strategies

• Geographical coverage
• Recruitment status
• Gender
• Age

6. Key Companies

• Type of players
• Company overview

7. Discontinued and Dormant Molecules

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at media@technavio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180913005416/en/